Genotype-specific combinatorial drug sensitivities in melanoma.

Slides:

Advertisements

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Advertisements

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

WEE1 inhibition forces S-phase–arrested cancer cells into mitosis.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

MAPK pathway inhibitors.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

PARPi combinations against HR-proficient tumors.

Figure 3 Drug cycling with collateral sensitivity

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

H-NS2 is upregulated in an hns mutant derivative of the strain E

Figure 2 Frequency and overlap of alterations

nab-Paclitaxel targets the tumor epithelial cells.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Whole-cell patch-clamp analysis of NAc cells.

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

Network Medicine Strikes a Blow against Breast Cancer

IL-10 upregulates IgG4 production by CD27+ B cells.

Sequencing and PDX technologies for the identification and validation of therapeutic targets in non–V600 mutant BRAF melanoma. Sequencing and PDX technologies.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Wild-type Ras does not antagonize myeloid transformation by NrasG12D.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Complementation of sos1 mutant.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Mutant BRAF Melanomas—Dependence and Resistance

Comparing drug sensitivity predictions from different data types in melanoma and endometrial cancer cell lines. Comparing drug sensitivity predictions.

TNFα is an important survival and growth signal for melanoma.

A, unsupervised hierarchical clustering of the expression of probe sets differentially expressed in the oral mucosa of smokers versus never smokers. A,

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

Heat map of genes for which CR significantly altered expression versus AL. Cluster analysis of genes significantly changed by the CR intervention compared.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

Drug sensitivities of IGROV1 cells to AGF94 and PMX at leucovorin (LCV) concentrations of 2 and 25 nmol/L. Drug sensitivities of IGROV1 cells to AGF94.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

A and B, mRNA expression relative to ERα (in%) for ZNF423 (A) and BRCA1 (B) for LCLs of known genotypes for variant (V) and WT chromosome 16 ZNF423 SNPs.

Tipifarnib combined with bortezomib induces cell death in diverse multiple myeloma and AML cell lines. Tipifarnib combined with bortezomib induces cell.

In vitro time course assays for four renal selective compounds.

Drug interaction signatures for GIST and benign osteoma cell lines representing all combinatorial data compiled in a 9 × 9 drug matrix. Drug interaction.

PTPH1 depends on its catalytic activity to increase ER nuclear accumulation and to enhance breast cancer sensitivity to TAM. A, effects of PTPH1 and PTPH1/DA.

WP1066 inhibits the progression of OCIM2 cells through the cell cycle.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

Effect of siltuximab on paclitaxel sensitivity in ovarian cancer drug resistant cells. Effect of siltuximab on paclitaxel sensitivity in ovarian cancer.

Tivantinib does not inhibit MET function.

Tivantinib behaves as an antimitotic agent.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Identification of compounds that enhance TMZ cytotoxicity in melanoma cells by screening the Spectrum Collection library. Identification of compounds that.

Combined inhibition of coamplified RTKs is required for response.

No single ALK mutations confer high-level resistance to lorlatinib.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.

BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro. BRAF-mutant melanoma cells are resistant to the antigrowth.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Preclinical trials in mouse models of APL

Validation of KMT2D function in MM23, MM2, and MM25 PDXs

Wild-type and oncogenic Ras differentially regulate cell proliferation

Regulation of signaling by wild-type and oncogenic Ras.

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Curative effect of W+T treatment in vivo.

Identification and characterization of activated integrin pathway module by signal transduction representation (A) and unsupervised hierarchical clustering.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Expression of PKM2 Y105F mutant in H1299 cells leads to decreased proliferation under hypoxic conditions, increased oxidative phosphorylation and reduced.

AXL is not necessary for maintenance of intrinsic resistance.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Kros of Single grf Knockout Mutants.

Presentation transcript:

Genotype-specific combinatorial drug sensitivities in melanoma. Genotype-specific combinatorial drug sensitivities in melanoma. A, unsupervised clustering of maximum growth inhibition achieved out of the 9 concentration combinations tested for each cell line (columns) for each unique drug pair (rows). Partitioning of mutant BRAF cultures (Cluster 1) and mutant RAS or WT melanoma cultures (Cluster 2) is readily apparent. B, frequency of agents that in pairwise combinations elicit a GI25 or higher effect level and 15% or more growth inhibition in the mutant BRAF group relative to the other 2 groups. C, as in B but for mutant RAS melanomas. Matthew A. Held et al. Cancer Discovery 2013;3:52-67 ©2013 by American Association for Cancer Research